10th Congress of the
European Association of Dermato-Oncology
Targeting CD30 in PTCL:
the why, which, and how
10 May 2014 9:30–10:30
Radisson Blu Hotel, Vilnius, Lithuania
Zeta Room, 1st Floor

Andreas Engert, MD


Andreas Engert, MD, is Professor of Internal Medicine, Haematology, and Oncology at the University Hospital of Cologne in Cologne, Germany. He received his medical degree from the Hannover Medical School in Hannover, Germany, followed by medical training at the same school and at the University Hospital of Cologne. From 1988 to 1990 he worked for the imperial Cancer Research Fund and at the Royal Free Hospital in London, UK on new immunotherapeutic approaches to cancer treatment.

After Professor Engert's return to Cologne his group focused on developing antibody-based immunotherapy for patients with malignant lymphoma, resulting in a number of experimental phase I/II clinical trials. He completed his postdoctoral lecture qualification in 1995 and was appointed Consultant; he then became Head of Staff in 1996 and Vice Director of the Department of Haematology and Oncology in 2000.

Professor Engert has published more than 400 original papers in journals including the New England Journal of Medicine, The Lancet, Nature Genetics, and the Journal of Clinical Oncology. He was appointed Coordinating Editor of the Cochrane Hematological Malignancies Group (CHMG) in 2000. After serving as secretary since 1999, he was elected Chairman of the German Hodgkin Study Group (GHSG) in 2007. The University of Belgrade awarded Professor Engert an honorary doctorate in May 2012, and in June 2012 he was elected as a European Hematology Association (EHA) Board of Directors councilor. He has received numerous awards for his scientific work, including the Ludwig Heilmeyer Medal, the Arthur Pappenheim Award, the Research Award of the University of Cologne, the Award of the German Cancer Society in 2011, and the Paul Martini Prize in 2013.

Disclosure Forms


Andreas Engert

Timothy Illidge

Christian Gisselbrecht
This meeting is an
Excerpta Medica activity.
Support for this educational activity is provided by
Takeda Oncology.